Application of medication composition containing BV6 in preparing medication for treating chronic insufficiency of supplying blood for brain

Abstract

An application of the medicinal composition composed of Naoyiqin, the extract of notoginseng, VB6 and VE in preparing the medicines for treating chronic cerebral ischemia is disclosed.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a pharmaceutical composition containing VB6 in the preparation of medicines for treating chronic cerebral insufficiency. Background technique [0002] The origin of the concept [0003] Chronic Cerebral Circulation Inefficiency (CCCI) refers to the state of reduced blood supply to the brain at the overall level (less than 40-60ml / 100g brain tissue / minute), rather than focal cerebral ischemia. It is a relatively new disease name proposed by foreign countries in the first 10 years. Clinically, some elderly or pre-senile patients who repeatedly complain of subjective symptoms such as heavy head and dizziness have neither focal signs of nerve damage nor brain CT abnormalities except fundus arteriosclerosis. Arteriosclerosis". It is well known that the concept and clinical diagnostic criteria of cerebral arteriosclerosis have been divergent for a long time. ...

AI Technical Summary

Problems solved by technology

[0033] 3. No focal neurological signs of the brain

[0043] 3. No focal neurological signs of the brain;

[0044] 4. CT\MRI without vascular organic brain changes;

[0056] At present, the drugs used in the clinical treatment of CCCI include: THA: cholinesterase inhibitor, GST-21: central N-choline receptor inhibitor, FK506: immunosuppressant, Nimsuperzine: Cox-2 inhibitor, etc. A good short-term clinical effect has been achieved, but the long-term effect needs further study

Images